Skip to main
BBOT

BBOT Stock Forecast & Price Target

BBOT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Oncology Therapeutics Inc. is considered to possess significant pipeline value due to its innovative therapeutic approaches targeting RAS and PI3Kα-driven cancers, with a focus on potential efficacy improvements through internal combinations of its clinical-stage assets. The company's advancement in clinical trials, particularly with BBO-8520 and BBO-10203, has demonstrated promising efficacy and safety profiles, addressing unmet needs arising from existing therapies that target specific mutations. Moreover, the presence of three wholly-owned assets in Phase 1 trials, coupled with promising early data, supports a premium valuation compared to its small and mid-cap peers in the biotechnology space.

Bears say

BridgeBio Oncology Therapeutics Inc faces significant risks that contribute to a negative outlook, primarily stemming from the potential for disappointing clinical results from its key drug candidates BBO-8520, BBO-10203, and BBO-11818, which could lead to reduced market penetration and prolonged timelines for regulatory approval. Additionally, the decline in median progression-free survival (mPFS) observed in Phase 3 studies for competing therapies highlights potential challenges in market competitiveness and effectiveness. Further complicating the financial outlook are concerns regarding reimbursement and commercialization strategies amidst a landscape of better-performing competitor products and the inherently higher recurrence risks associated with certain cancers targeted by the company's pipeline.

BBOT has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Oncology Therapeutics Inc (BBOT) Forecast

Analysts have given BBOT a Buy based on their latest research and market trends.

According to 7 analysts, BBOT has a Buy consensus rating as of Apr 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Oncology Therapeutics Inc (BBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.